<code id='C5CB291277'></code><style id='C5CB291277'></style>
    • <acronym id='C5CB291277'></acronym>
      <center id='C5CB291277'><center id='C5CB291277'><tfoot id='C5CB291277'></tfoot></center><abbr id='C5CB291277'><dir id='C5CB291277'><tfoot id='C5CB291277'></tfoot><noframes id='C5CB291277'>

    • <optgroup id='C5CB291277'><strike id='C5CB291277'><sup id='C5CB291277'></sup></strike><code id='C5CB291277'></code></optgroup>
        1. <b id='C5CB291277'><label id='C5CB291277'><select id='C5CB291277'><dt id='C5CB291277'><span id='C5CB291277'></span></dt></select></label></b><u id='C5CB291277'></u>
          <i id='C5CB291277'><strike id='C5CB291277'><tt id='C5CB291277'><pre id='C5CB291277'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:65
          Three boxes of Wegovy stands in a line — coverage from STAT
          Steffen Trumpf/picture alliance/Getty Images

          WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

          Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

          advertisement

          Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Novo acquires Inversago for up to $1 billion
          Novo acquires Inversago for up to $1 billion

          LISELOTTESABROE/Scanpix/AFPviaGettyImagesFreshoffofthenewsthatitsdrugWegovymaynotjusthelppeoplelosew

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Average age of first period drops to 11.9 years, study shows

          AdobeMenstruationisacriticalindicatorofhealth.Whetherandwhensomeonewithauterusgetstheirperiod—forthe